NFX Nuformix Plc

TIDMNFX

RNS Number : 3775K

Nuformix PLC

24 August 2023

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.

The results of the proxies appointing the Chair of the meeting are reported below:

 
                Resolution               Ordinary/      For                Against               Total 
                                          Special                                              votes cast 
                                                       No. of       %      No. of       % 
                                                        votes               votes 
     To re-appoint Daniel 
 1    Gooding as a director              Ordinary    94,720,614   99.67    312,357    0.33%   95,032,971 
     To re-appoint Julian 
 2    Gilbert as a director              Ordinary    94,720,614   99.67    312,357    0.33%   95,032,971 
     To re-appoint s 
      Madeleine Kennedy 
 3    as a director                      Ordinary    92,448,034   99.66    312,357    0.34%   92,760,391 
     To authorise the 
      Directors to allot 
 4    shares.                            Ordinary    92,082,014   96.19   3,652,015   3.81%   95,734,029 
                To authorise the 
                 Directors to disapply 
 5               pre-emption rights.      Special    92,082,014   98.52   1,379,435   1.48%   93,461,449 
                To authorise the 
                 Company to purchase 
 6               its own shares.          Special    92,306,372   96.32   3,527,841   3.68%   95,834,213 
         To authorise calling 
          of a general meeting 
          on 14 clear days' 
 7        notice.                         Special    93,093,402   97.14   2,740,811   2.86%   95,834,213 
 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 744,309,368 ordinary shares of GBP0.001 each.

Enquiries:

 
 Nuformix plc 
 Dr Daniel Gooding, Executive Director      Via IFC Advisory 
  Dr Julian Gilbert, Non-executive 
  Chairman 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes (Corporate Broking)             +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFFFTLISFIV

(END) Dow Jones Newswires

August 24, 2023 08:22 ET (12:22 GMT)

Nuformix (LSE:NFX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Nuformix (LSE:NFX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025